Sinopharm Tech entered into the Licensing and Master Service Agreement with anti-counterfeiting device service provider


    Strengthen the uniqueness of anti-counterfeiting solutions

    HONG KONG, July 5, 2021 /PRNewswire/ -- Sinopharm Tech Holdings Limited ("Sinopharm Tech" and its subsidiaries, together, the "Group", stock code: 8156) is pleased to announce that, Shenzhen Guoke Anti-counterfeiting Technology Company Limited, a direct wholly-owned subsidiary of Sinopharm Tech (as the Licensee) entered into the Licensing and Master Service Agreement in relation to the provision of the Total Solutions on anti-counterfeiting device product with Shenzhen Ficus Technology Holdings Ltd. (as the Licensor) yesterday. The Licensing and Master Service Agreement commenced today, unless terminated in accordance with provisions of clauses of the Licensing and Master Service Agreement, continue in full force and effect until 30 June 2024.

    The Group is actively exploring the anti-counterfeiting market and has experience in welfare and sports lottery industries for years. In the past two years, the Group has focused on the opportunities in the growing anti-counterfeiting market. In 2019, the Group started the discussion and exploring the sales of anti-counterfeit for goods and online anti-counterfeiting information verification platform to the market and has achieved concrete results. The Group has contracted with three brand owners in the tea leaves, natural food and cosmetics e-commerce platform industries for the application of the Devices on the brand owners' products and shall be required to deliver the Devices in accordance with the agreements entered into. Therefore, the Group is under actual demand to obtain authorization from the Licensor for the use of the Total Solutions and the Devices to comply with the requirement of necessary approval for conducting the relevant business and support.

    The Terms and Conditions of the Licensing and Master Service Agreement

    Subject to the terms and conditions of the Licensing and Master Service Agreement, the Licensor agrees to provide the following services (collectively the "Total Solutions") to the Licensee from time to time which including to: (i) grant the Licensee during the term of the Licensing and Master Service Agreement, an exclusive and royalty-bearing license to the Patents to use, sell, and offer to sell the Devices in the PRC; and (ii) provide services in relation to (a) design, production arrangement, material procurement and quality control, and customisation service of the Devices pursuant to the specification required by the Licensee and with the quality satisfactory to the Licensee at reasonable costs under each individual purchase order, and (b) design, development and customization of the online anti-counterfeiting information verification platform and the relevant services based on the Licensed Patents Rights.

    Exclusivity

    The License granted by the Licensor to the Licensee is on an exclusive basis as far as it relates to the State-owned Enterprise Customers only. The Licensor is not entitled to license the Patents and Devices to any third parties for the supply of Devices or Total Solutions to any State-owned Enterprise Customer or contract directly with any State-owned Enterprise Customer for such supply.

    The Proposed Annual Caps

    The Board proposes the Proposed Annual Caps under the Licensing and Master Service Agreement for each of the three years ending 30 June 2024 are HK$8.3 million, HK$8.8 million and HK$9.3 million respectively. The Proposed Annual Caps were determined by the Company after taking into account of (i) the potential demand of anti-counterfeiting lottery devices from the customers of the Group based on the relevant executed agreements and potential agreements to be entered into between the Group and its customers; (ii) the potential growing trend of the anti-counterfeiting lottery market in the PRC with reference to the generally optimistic prospect of the anti-counterfeiting market in the PRC; and (iii) other relevant principal terms under the Licensing and Master Service Agreement.

    Information on the Licensor

    Shenzhen Ficus Technology Holdings Ltd. is a company incorporated in the PRC with limited liability and is the registered holder of the Patents, and is engaged in the business of provision of services in relation to the design, development and provision of anti-counterfeiting devices in the PRC. The Patents have been registered in the PRC (registration number are ZL 201921449828.X and ZL 201921579150.7), Japan (registration number are 3229334 and 3229631) and Hong Kong (registration number are HK30032261 and HK30032942), and applications for registration in Taiwan, Indonesia, Korean and Malaysia are in progress.

    Mr. CHAN Ting, Executive Director and Chief Executive Officer of Sinopharm Tech, said, "In recent years, there is a rapid development in the various consumer segments in China, especially for the rise of mid-to-high-end market, which leads to an indication that there is a huge demand for anti-counterfeiting technology from brand owners. The agreement will further strengthen the anti-counterfeiting devices including the unique lottery component with the benefits of uniqueness and credibility with criminal sanctions for counterfeiting lottery tickets. The Devices are easily recognized by the consumers and welcomed by the brand owners. The Group will seize the opportunity to realize the growth of the recently developed business while creating new income streams for the Group."

    About Sinopharm Tech Holdings Limited

    Sinopharm Tech Holdings Limited is a company that provides integrated solutions on lottery and "Internet Plus", as well as the manufacturing of personal protective equipment. Sinopharm Tech is engaged in (i) the provision of lottery-related services; (ii) Internet plus services (solution and supply chain); (iii) manufacturing and distribution of personal protective equipment; and (iv) other services. In 2019, the Group successfully introduced Sinopharm Traditional Chinese Medicine Co. Ltd., a member of China Traditional National Chinese Medicine Co., Ltd., as one of the main strategic shareholders.

    The Group has been deeply involved in China's welfare lottery and sports lottery industries for more than 20 years, and is committed to bringing different innovative solutions to the industry, from lottery systems to interactive marketing to the latest anti-counterfeiting business. The Group is being granted the licensed patent rights and being an exclusive distributor for supplying anti-counterfeiting devices to state-owned enterprise customers in PRC, paving the way for the Group to achieve the cross-industrial and cross-regional market penetration and make a profit.

    Caishen.Co - Primary Data for China Secondary Investment and Stock Markets
    PR Newswire is the premier global provider of news release distribution and multimedia platforms that enable marketers, corporate communicators, sustainability officers, public affairs and investor relations officers to leverage content to engage with all their key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, optimize and target content – from rich media to online video to multimedia – and then distribute content and measure results across traditional, digital, mobile and social channels. Combining the world's largest multi-channel distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and the Asia-Pacific region, and is a Cision company.

    RELATED NEWS